Inactive Instrument

Press Releases Synthetic Biologics Inc Nyse

Equities

US87164U1025

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 25	AQ
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	Apr. 23	AQ
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting	Apr. 22	AQ
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting	Apr. 08	AQ
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results	Mar. 25	AQ
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results	Mar. 19	AQ
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference	Mar. 11	AQ
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma	Feb. 07	AQ
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference	Jan. 16	AQ
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results	Nov. 13	AQ
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results	Nov. 06	AQ
Theriva™ Biologics to Participate in the BIO-Europe Conference	Nov. 02	AQ
Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer	Nov. 02	AQ
Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023	23-10-23	AQ
Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	23-10-16	AQ
Theriva Biologics to Participate in the Emerging Growth Conference	23-09-28	AQ
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results	23-08-08	AQ
Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma	23-08-02	AQ
Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results	23-08-01	AQ
Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients	23-04-13	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Synthetic Biologics Inc Nyse

Equities

US87164U1025

Press Releases

Filters